Highlights

  • Alcidion Group shares jumped 6.06% on 18 May 2026, as investors reacted positively to the latest Acquisition update.
  • ALC has signed an Asset Sale Agreement to acquire the Kyra flow products from Telstra Health.
  • Consideration is A$3.0M upfront plus up to A$1.0M earn-out, funded from existing cash reserves.
  • FY26F Revenue of A$3.7M (90%+ recurring) and underlying EBITDA ~A$1.1M imply an upfront 2.7x EBITDA multiple.
  • Adds ~33 long-standing customers (Top 10 average tenure ~10 years) across 5 of 6 Australian states.
  • Transaction expected to be immediately Earnings accretive on completion (anticipated end June 2026).

Alcidion Group Limited (ASX:ALC), a leading provider of enterprise patient flow solutions, has signed an Asset Sale Agreement (ASA) to acquire the Business and Assets of Kyra Patient Flow Manager, Kyra Queue Manager and Kyra IQ (collectively, the Kyra flow products) from Telstra Health. The 18 May 2026 ASX announcement is positioned by Alcidion as further strengthening its leading position in the Australian patient flow market and aligned with the company’s strategy to drive sustainable, high-Margin, Recurring Revenue growth.

For investors monitoring ALC ASX announcements, the deal is structured to be immediately earnings accretive on completion (anticipated end June 2026), reflecting the Kyra flow products’ attractive recurring revenue and margin profile. This article summarises the verified terms, strategic rationale and risks. Following the release of update, Alcidion Group shares rose 6.06% to AUD 0.10 during the afternoon Trading session on 18 May 2026, and remains up 31.25% over the past year.

What Investors Need to Know

Under the agreement, Alcidion will pay A$3.0 million upfront on a cash free and Debt free basis, subject to customary completion adjustments, plus up to A$1.0 million in earn-out payments tied to recurring revenue metrics assessed over the 12-month period post completion. The transaction will be funded from Alcidion’s existing cash reserves; as of 31 March 2026, the company held A$15.1 million of cash and no debt. Completion is expected to occur by the end of June 2026, subject to satisfying closing conditions.

The Kyra flow products business is expected to generate FY26 forecast revenue of A$3.7 million, with more than 90% of revenue from recurring support and maintenance contracts. Underlying EBITDA is forecast at approximately A$1.1 million, implying an upfront FY26 EBITDA multiple of 2.7x.

About the Kyra Flow Products

The Kyra flow products comprise three complementary inpatient and outpatient hospital-focused patient flow solutions. Kyra Patient Flow Manager provides clinicians and administrative teams real-time access and oversight of a patient’s hospital journey from admission through to discharge, enabling proactive decision-making to streamline bed management and internal resourcing. Kyra Queue Manager is a comprehensive outpatient solution enabling patient check-ins, wayfinding, referral management, triage and billing capability. Kyra IQ is a data Warehouse that consolidates health data from multiple disparate systems into real-time operational dashboards and administrative reports.

Strategic Rationale

According to Alcidion, the Kyra flow products business has customers in five of six Australian states, with a significant presence across the Queensland market — strategically important given Alcidion’s recent 5-year contract with Gold Coast Health, also a Kyra flow products customer. The deal adds several new customers in Victoria across public and private sectors, building on Alcidion’s patient flow presence at Hume, Peninsula Health, Western Health and Alfred, among others. Importantly, only 2 of the 33 Kyra customers are existing Alcidion customers, providing a meaningful opportunity to broaden Alcidion’s footprint.

Driven by the critical and embedded nature of the Kyra solution, the average Top 10 customer relationship is approximately 10 years, with contract terms ranging from 1 to 3 years and the majority on rolling annual contracts. The acquisition expands Alcidion’s Leadership in patient flow across Australia, New Zealand and the United Kingdom, and complements its flagship Miya Precision platform.

Management Commentary

Alcidion CEO and Managing Director Kate Quirke said the acquisition is “highly complementary to our core business and further consolidates our market position in the Australian patient flow market,” adding that there is “strong strategic and financial alignment” as the company continues to build a scaled, recurring revenue-driven health technology company. Ms Quirke also highlighted Alcidion’s intent to maintain a relationship with Telstra Health to Leverage the complementary nature of their respective product suites.

Telstra Health Managing Director Elizabeth Koff AM said Telstra Health is “building a care intelligence ecosystem” and is “making clear choices about where we focus, where we invest, and where we partner.” She added that Alcidion was chosen because the company “brings strong capability, deep industry expertise and a proven track record supporting hospitals,” and that Telstra Health’s priority is to ensure a smooth transition for Kyra flow products to Alcidion with continuity of service and support for customers.

Company Background

Alcidion Group Limited (ASX: ALC) is a healthcare informatics company whose flagship product, Miya Precision, aggregates meaningful information into centralised dashboards, supports interoperability, facilitates communication and task management in clinical and operational settings, and delivers clinical decision support at the point of care. Since listing on the ASX in 2016, Alcidion has acquired multiple healthcare IT companies and now operates across Australia, New Zealand and the United Kingdom.

Why Investors Are Watching ALC

Market Participants are watching ALC for evidence that the Kyra acquisition can deliver the disclosed financial profile and broaden Alcidion’s presence into customers and geographies where it previously had limited exposure. Investors may also be watching the company’s pipeline of Miya Precision opportunities arising from the expanded Kyra customer relationships.

Sector Outlook

Patient flow continues to be a critical pain point across healthcare settings, with an ageing population and rising hospital admissions putting pressure on enterprise digital solutions that simplify decision support and reduce administrative burden. Recurring-revenue health IT models with embedded customer relationships are typically valued for their predictability and the operational criticality of their products.

Risks and Uncertainties

Risks include integration and execution risk in transitioning the Kyra customer base, earn-out payment risk based on recurring revenue performance, potential customer churn during transition, competitive intensity in the patient flow market, and broader Macroeconomic Factors affecting healthcare IT spending. Completion is subject to satisfying closing conditions, anticipated by end June 2026.

What Could Happen Next

Investors may watch for completion of the transaction by end June 2026, integration progress thereafter, any updates on the achievement of earn-out thresholds in the 12-month period post completion, and the realisation of cross-sell opportunities for Miya Precision into the Kyra customer base.

Conclusion

The 18 May 2026 ALC announcement positions Alcidion to materially expand its patient flow footprint via the Kyra acquisition, with attractive recurring revenue, an embedded customer base and an EBITDA-accretive deal structure. Investors are encouraged to read the full ASX release and monitor completion and integration progress in 2026.